Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR8070)
Name
S-1
Synonyms
Fluoropyrimidine anticancer agent
    Click to Show/Hide
Disease Gastrointestinal stromal tumor [ICD-11: 2B5B] Phase 3 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Cepharanthine      Stephania delavayi     Click to Show/Hide the Molecular Data of This NP
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression DPYD  Molecule Info 
Pathway MAP
Down-regulation Expression TYMS  Molecule Info 
Pathway MAP
                    In-vitro Model HSC-2 CVCL_1287 Oral cavity squamous cell carcinoma Homo sapiens
B88 Oral squamous cell carcinoma Homo sapiens
                    In-vivo Model B88 or HSC2 cells (1*106) were suspended in 0.1 mL of serum-free medium and injected into the subcutaneous tissue of 5-week-old nude mice.
                    Experimental
                    Result(s)
Combined therapy of cepharanthine and S-1 exerted antitumor effects on human OSCC xenografts markedly and significantly induced apoptotic cells in tumors treated with cepharanthine plus S-1.
          Peginterferon alpha 2b      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)
Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC.
Target and Pathway
Target(s) ATP synthase F(0) complex C1 (ATP5MC1)  Molecule Info  [4]
ATP synthase F(0) complex C2 (ATP5MC2)  Molecule Info  [4]
ATP synthase F(0) complex C3 (ATP5MC3)  Molecule Info  [4]
References
Reference 1 ClinicalTrials.gov (NCT03941561) S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
Reference 2 Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2009 Apr;29(4):1263-70.
Reference 3 Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology. 2008;75 Suppl 1:106-13.
Reference 4 Single-molecule analysis of F0F1-ATP synthase inhibited by N,N-dicyclohexylcarbodiimide. J Biol Chem. 2013 Sep 6;288(36):25717-25726.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China